This collection of must-read MCT reviews provides an in-depth view on target identification and the development of cancer therapeutics. MCT welcomes submissions of timely reviews on hot topics and original research in small molecule therapeutics, large molecule therapeutics, cancer biology and signal transduction, companion diagnostics and cancer biomarkers, and models and technology.
Genomically Driven Tumors and Actionability Across Histologies: BRAF-Mutant Cancers as a Paradigm
Michelle L. Turski, Smruti J. Vidwans, Filip Janku, Ignacio Garrido-Laguna, Javier Munoz, Richard Schwab, Vivek Subbiah, Jordi Rodon and Razelle Kurzrock
Molecular Cancer Therapeutics April 2016.
The Role of PGC1α in Cancer Metabolism and its Therapeutic Implications
Zheqiong Tan, Xiangjian Luo, Lanbo Xiao, Min Tang, Ann M. Bode, Zigang Dong and Ya Cao
Molecular Cancer Therapeutics May 2016.
ATM Mutations in Cancer: Therapeutic Implications
Michael Choi, Thomas Kipps and Razelle Kurzrock
Molecular Cancer Therapeutics August 2016.
Mechanisms of Resistance to Antibody-Drug Conjugates
Frank Loganzo, Matthew Sung and Hans-Peter Gerber
Molecular Cancer Therapeutics December 2016.
Molecular Cancer Therapeutics Editorial Office
American Association for Cancer Research | Publications Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (267) 765-1090 | E-mail: email@example.com